Q2 FY12 Performance Highlights:

• Consecutive 12 quarters of high revenue growth with total revenue reaching US$62.2M (71% year-on-year growth)

• Sales of Interventional Cardiology Products (“IVP”) recorded robust year-on-year increase of 31% at US$38.4M, driven primarily by the strong sales of the Company’s flagship BioMatrix™ family of drug-eluting stents (“DES”)

• Net profit increased 171% year-on-year to US$22.9M

• Completed acquisition of the remaining 50% equity in JW Medical Systems Limited (“JWMS”) on 3 October 2011

• Terumo Corporation, the Company’s licensing partner, continues to record strong revenue growth after it commenced sales of the Nobori DES in Japan in May. This led to a five-fold increase in licensing revenue, year-on-year, for the Company